Who is sponsoring NCT03043846?

NCT03043846 is sponsored by Association de Recherche Clinique en Rhumatologie.

What drugs are being tested in NCT03043846?

Interventions in NCT03043846: Follow-up every 3 months during 1 year (data collection in eCRF), Follow-up every month to follow the pre-defined strategy.

What condition does NCT03043846 study?

NCT03043846 studies Axial Spondyloarthritis.

Is NCT03043846 still recruiting?

NCT03043846 is currently completed. Last updated 27 September 2019.

Last reviewed 2019-09-27 · How we verify

NCT03043846: TICOSPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)

Completed Last updated 27 September 2019

What this trial tests

trial testing Follow-up every 3 months during 1 year (data collection in eCRF) in Axial Spondyloarthritis in 163 participants. Completed in 18 June 2019.

Timeline

30 November 2016

Primary endpoint
18 June 2019

18 June 2019

Quick facts

Lead sponsor	Association de Recherche Clinique en Rhumatologie
Status	Completed
Study type	OBSERVATIONAL
Enrollment	163
Start date	30 November 2016
Primary completion	18 June 2019
Estimated completion	18 June 2019
Sites	18 locations across Belgium, France, Netherlands

Drugs / interventions tested

Follow-up every 3 months during 1 year (data collection in eCRF)
Follow-up every month to follow the pre-defined strategy

Conditions studied

Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →

Sponsor

Association de Recherche Clinique en Rhumatologie

Who can join

Adults 18 to 65, any sex, with Axial Spondyloarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e. usual care) in patients with axial spondyloarthritis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.
Molto A, López-Medina C, Van den Bosch FE, Boonen A, et al · · 2021 · cited 83× · PMID 33958325 · DOI 10.1136/annrheumdis-2020-219585
Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.
Garrido-Cumbrera M, Hillmann O, Mahapatra R, Trigos D, et al · · 2017 · cited 47× · PMID 28600789 · DOI 10.1007/s40744-017-0066-2
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Poddubnyy D, Sieper J. · · 2020 · cited 24× · PMID 32691259 · DOI 10.1007/s11926-020-00924-5
Treat-to-target in axial spondyloarthritis: an observational study in daily practice.
Beckers E, Boonen A, Webers C, Ten Klooster P, et al · · 2022 · cited 8× · PMID 34175950 · DOI 10.1093/rheumatology/keab516
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study.
Proft F, Schally J, Brandt HC, Brandt-Juergens J, et al · · 2022 · cited 7× · PMID 35368376 · DOI 10.1177/1759720x221085951
Recent advances in managing axial spondyloarthritis.
Agrawal P, Machado PM. · · 2020 · cited 6× · PMID 32704350 · DOI 10.12688/f1000research.22577.1
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.
Liew JW, Dubreuil M. · · 2020 · cited 5× · PMID 32340706 · DOI 10.1016/j.rdc.2020.01.011
Spondyloarthritis mass cytometry immuno-monitoring: a proof of concept study in the tight-control and treat-to target TiCoSpA trial.
Koppejan H, Beyrend G, Hameetman M, Abdelaal T, et al · · 2023 · PMID 37306812 · DOI 10.1007/s10067-023-06637-1

Verify or expand the search:

Other recruiting trials for Axial Spondyloarthritis

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting

Other Association de Recherche Clinique en Rhumatologie trials

Trials by the same sponsor.

NCT03039088 — PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Ef · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03043846 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Association de Recherche Clinique en Rhumatologie
Last refreshed: 27 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03043846.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing